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Abstract
Background: This study’s aim was to develop a first quantification of the frequency and costs of adverse drug
events (ADEs) originating in ambulatory medical practice in Germany.
Methods: The frequencies and costs of ADEs were quantified for a base case, building on an existing cost-of-
illness model for ADEs. The model originates from the U.S. health care system, its structure of treatment
probabilities linked to ADEs was transferred to Germany. Sensitivity analyses based on values determined from a
literature review were used to test the postulated results.
Results: For Germany, the base case postulated that about 2 million adults ingesting medications have will have
an ADE in 2007. Health care costs related to ADEs in this base case totalled 816 million Euros, mean costs per case
were 381 Euros. About 58% of costs resulted from hospitalisations, 11% from emergency department visits and
21% from long-term care. Base case estimates of frequency and costs of ADEs were lower than all estimates of the
sensitivity analyses.
Discussion: The postulated frequency and costs of ADEs illustrate the possible size of the health problems and
economic burden related to ADEs in Germany. The validity of the U.S. treatment structure used remains to be
determined for Germany. The sensitivity analysis used assumptions from different studies and thus further
quantified the information gap in Germany regarding ADEs.
Conclusions: This study found costs of ADEs in the ambulatory setting in Germany to be significant. Due to data
scarcity, results are only a rough indication.
Background
Medications are used to cure or slow disease processes,
to reduce symptoms and to improve quality of life [1].
However, all medications may have disadvantageous
effects, which may be reported as drug related problems
(DRPs) or adverse drug events (ADEs). Studies of DRPs
report actual or potential problems which interfere with
the desired health outcome, a spectrum ranging from
adverse consequences (such as side effects) to lack of
effectiveness [2]. In contrast, studies of ADEs report
injuries due to the use of a drug [3]. ADEs may be due
to: 1) medication errors; 2) adverse drug reactions
(ADRs), i.e. unintended reactions occurring at usual
doses [4]; 3) interactions with other drugs, underlying
diseases or the patient (idiosyncratic reactions and aller-
gies) or 4) errors in prescribing, dispensing, adhering to
and monitoring medications [1,5].
Literature reviews regarding the number of hospital
admissions due to ADRs have reported various results.
One review in 2002 reported that ADRs account for
4.9% of hospital admissions [6] whereas another review
in 1997 reported that 5.8% of all admissions to medical
departments [4] were drug-related. Only 2 studies have
reported drug-related hospitalisations to internal medi-
cine wards in Germany. Dormann [7] reported that 3.8%
of medical admissions were drug-related, while Schnee-
weiss reported that 2.4% of all medical admissions over
30 months were drug-related [8].
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ranging from 3.7% (range 1.4-15.4) if all hospital admis-
sions are considered [10] to 30.7% if only admissions to
medical department are considered [11]. Preventable
drug-related admissions were associated with prescribing
problems (30.6%), adherence problems (33.3%) and
monitoring problems (22.2%) [10].
In US emergency departments, 1/3 of ADEs treated in
persons over 65 were caused by warfarin, insulin and
digoxin, all having a narrow therapeutic index and a
high risk of overdose or toxicity [12]. Similarly in Ger-
many, antithrombotics, NSAIDs, insulin, salicylates,
digoxin and calcium antagonists have been reported to
account for 70% of the medications involved in drug-
related hospitalisations [8]. Medications responsible for
preventable drug-related admissions include antiplatelets
(50%), aspirin (16%), diuretics (15.9%), non-steroidals
(11%) and anticoagulants (8.3%) [10].
It is estimated that in the USA, ADEs occur at a rate
of 2-7/100 admissions in hospital [9] and at a rate of 3%
in adult primary care outpatients [13], thus imposing a
considerable burden on healthcare systems. A review of
the international literature regarding costs of ADEs
from the hospital perspective reported that average hos-
pital costs ranged from 904€ to 5,783€ per ADE with
both the lowest and highest values reported in the USA
[14]. Annual hospitalisation costs for ADEs in Germany,
were estimated, based on a literature review, to total
1,050 million DM (540 million Euros) in 1997 [11].
Since 30% of these adverse events were possibly preven-
table, at least 180 million Euros were unnecessary costs
[11]. However, these calculations did not consider out-
patient treatment costs of ADEs.
Costs associated with drug-related mortality and mor-
bidity in ambulatory care have been estimated using a
probability-pathway model for the USA [15,16]. The
model is based on probabilities of resource use esti-
mated by clinical experts for the US healthcare system.
It identifies and structures the possible resource use
related to adverse drug events occurring in the ambula-
tory setting. Estimates of costs associated with drug-
related morbidity and mortality exceeded $177.4 billion
US dollars for the year 2000, with hospital admissions
accounting for nearly 70% of total costs. This equates to
13% of the total US expenditures for health in 2000
(1,328 billion US dollars according to OECD data [17]).
Aim
Previous studies for Germany have reported the percent
of hospitalisations due to ADRs and the associated costs
for the hospital admission [7,8]. However, the burden of
morbidity, mortality and costs of ADEs originating and
occurring in ambulatory medical practice remains
unknown. It was our objective to estimate morbidity
and costs associated with adverse drug events occurring
in the ambulatory setting in Germany. To estimate the
frequency and costs of ADEs occurring in the context of
outpatient drug treatment, the drug-related mortality
and morbidity cost-of-illness model developed for the
US was adapted to incorporate available German data.
Sensitivity analyses were performed using rates of ADEs
and healthcare utilisation found in the literature.
Methods
Model to determine the frequency and costs of ADEs
Parts of the drug-related morbidity and mortality cost-
of-illness-model [15,16] were used to simulate the mor-
bidity and costs of ADEs in Germany. This model
d e s c r i b e so u t c o m e sa n dc o s t sa s s o c i a t e dw i t hd r u g -
related problems (DRPs) from the perspective of third
party payers but it excludes illicit drug use and DRPs
originating in institutional settings. In the model, drug
related problems are divided into three mutually exclu-
sive sequences of events: 1) treatment failure 2) new
medical problem (NMP) 3) treatment failure and new
medical problem (TF/NMP). The structure of the model
is shown in Figure 1. The probability of these sequences
of events, or that ‘no DRP occurs’ and the conditional
probabilities of healthcare utilisation if a DRP developed
were estimated by a panel of clinical experts for the
USA [15,16]. In the model, the healthcare utilisation
endpoint is mostly mutually exclusive, i.e. if the patient
is hospitalised, costs for previous consultations to the
physician for the DRP are not considered and for long-
term care, no prior hospitalisation or physician visit is
included. This results in a systematic downward bias in
the costing of these healthcare resources. In the case of
death, the cost of prior hospitalisation is included as a
cost of death. However, one can imagine that some
patients with a severe ADE will die before reaching the
hospital. Since the aim of this study is to estimate the
frequency and costs of ADEs and the study used as a
source of ADEs [8] did not document treatment failures,
only the sequences of events for NMP and TF/NMP are
included in the present calculations, the part of the
model enclosed by a circle in Figure 1.
In the paper by Ernst et al. [16], the number of ADEs
is calculated based on a cohort of patients making a
total number of 734,493,000 physician visits. Since 90%
of the German population is insured with social health
insurance, healthcare facilities are used more frequently
than in the USA. There were 7.4 physician visits per
capita in Germany in 2006 compared to 3.8 in the USA
according to OECD [17]. Similarly, prescription prac-
tices between Germany and the USA may differ consid-
erably. However, it is conceivable that the likelihood of
requiring healthcare services, such as hospitalisation,
will be similar between the Germany and the USA if an
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node “drug prescribed” will be used for the present cal-
culations. Our final probabilities are the result of multi-
plying the first node (NMP or TF/NMP) with the
probability of resource utilisation. For example, in the
paper by Ernst et al. [16], the final probability of “no
therapy” for a “new medical problem” was 0.633 ×
0.105 × 0.146 = 0.010. In our paper, we did not include
the probability of drug therapy in the calculation
(0.633), so that the probability of “No therapy” for a
Figure 1 Probabilities of morbidity and mortality associated with medication intake used in the modelling approach.E n c l o s e di nt h e
oval is the part of the model used for the scenario. Probability of drug prescription in the original model was 0.55, and no drug was 0.45.
Overall outcome probabilities obtained by multiplying probability of type of drug-related problem with probability of outcome of drug-related
problem (probabilities originate from the model published by Ernst et al., 2001 [17]).
Stark et al. BMC Health Services Research 2011, 11:9
http://www.biomedcentral.com/1472-6963/11/9
Page 3 of 9“new medical problem” is 0.0153. Our adapted probabil-
ities are shown in Figure 1. As hospitalisations are
included in the model as hospitalisations and death, the
total number of hospitalisations is divided between these
categories, 97.9% as hospitalisations and 2.1% as death.
The probabilities of the types of resource utilisation
(physician visit, additional treatment, emergency depart-
ment visit, hospitalisation, long-term care and death) of
the 2 model arms, as shown in Figure 1 were added
together to obtain overall probabilities for the various
types of resource utilisation for ADEs. Overall probabil-
ities of resource use for ADEs were that 12% of medica-
tion users will require a physician visit (4% only
consultation and 8% additional treatment), 2% an emer-
gency department visit, 1% a hospitalisation, 0.3% long-
term care and 0.02% will die.
Sources of Costs of Resource Utilisation
To calculate the hospital costs of ADEs in the year 2007,
the adverse drug reactions described in the Schneeweiss
paper [8] were assigned possible ICD 10 codes (3 posi-
tions). Using data from the Federal Office of Statistics
f o rp a t i e n t so v e r2 0y e a r so fa g e ,t h es u mo fh o s p i t a l
days reported for the possible ICD codes for each
described adverse drug reaction was divided by the total
number of patients with the ICD code to calculate an
average length of stay. The calculated average length of
stay was multiplied with the average cost per hospital
day for general hospitals, 437€ [ 1 8 ] .T h eI C Dc o d e so f
the adverse drug reactions, the number of patients per
ICD code, number of hospital days per ICD code and
the average cost per admission per adverse drug reac-
tion is shown in Additional File 1. The final cost of hos-
pital stay was calculated as the average cost of the
described adverse drug reaction weighted according to
its prevalence as reported by Schneeweiss [8]. The
assignment of adverse drug reactions, their proportion
in each drug class and the calculated weights and total
costs are shown in Additional File 2. The final calcu-
lated cost of hospital stay (3,452.11€) was the weighted
average cost of the described adverse drug reactions.
Hospital admission costs are also included in the costs
of death. The costs of other resource utilisation were
determined as follows. The cost of an emergency
department visit was assumed to equal the cost of one
day in hospital (437€) [18]. The average cost of a pre-
scribed medication for the German statutory health
insurance system, which covers about 90% of the resi-
dent population, was 42.62 Euro in 2007 [19]. The cost
of a physician visit was calculated based on the average
contact value of a general practitioner and specialists of
internal medicine with and without family practice
responsibilities [20] in 1999 (16.20€ in 1999). The con-
tact value was extrapolated to 2007 using price increases
in physician reimbursement per case [21], which aver-
aged 4.4% annually between 1999 and 2007. The value
for 2007 was calculated to be 22.62 Euro per visit. Aver-
age costs for long-term care [22] in 2007 were calcu-
lated by dividing total expenditures for long term care
in the year 2007 [23] (18.34 billion Euros) by the total
number of recipients receiving benefits [24] (2.03 mil-
lion). This average includes persons receiving benefits
for the whole year or less, but it was assumed that the
majority of persons would receive benefits for the whole
year. This value was divided by 12 to obtain the
monthly rate. The time points at which persons started
to require long-term care for an ADE were assumed to
be equally distributed across the year and among the
persons requiring long-term care. Since expenditures
were not reported according to age-groups, the overall
average was used, which amounted to 4,890 Euro. Mul-
tiple visits to any healthcare facility were not accounted
for since these data were not available for Germany.
This cost calculation aimed to determine the excess
costs of ADEs and thus the costs of initial treatment
were not included, since they occur regardless of a ADE.
Source of the Number of Hospitalisations due to ADEs
Since the only available data for Germany is the percent
of hospitalisations related to adverse drug events [7,8],
the model was adapted to be based on this data. The rela-
tionship between the probabilities is used to calculate
resource utilisation from the number of ADEs requiring
hospitalisation (ie. 4 times as many patients require only
a physician visit compared to those requiring hospitalisa-
tion, the calculated factors are shown in Table 1). The
number of hospitalisations due to ADEs were calculated
based on the Schneeweiss study [8], whereas the Dor-
mann study [7] was used in the sensitivity analysis.
Schneeweiss reported that 2.4% of all hospital admissions
to medical wards over 30 months in 2 German cities
(total of 3 hospitals) were drug-related leading to an esti-
mate of the expected number of drug-related admissions
of adults of 139,405 based on the published number of
admissions to medical wards [25] (5,808,544 admissions
in 2007) for the ages 20 and older. All other health
resource use was calculated in relationship to the number
of drug-related hospitalisations.
Sensitivity Analyses
In order to test estimates based on the model, MED-
LINE was searched for studies reporting the frequency
of ADEs in adults in the ambulatory setting published
after 1990. Studies including chemotherapeutic agents
or only certain diseases or specific ADEs were excluded.
The studies found in this search are listed and summar-
ized in Additional File 3. Rates of healthcare resource
use reported by the studies for outpatient services (e.g.
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department, and hospitalisations are shown in Table 2.
The table shows the reported rates of healthcare use
and adjusted rates of healthcare use according to the
reported population taking medications (see also Addi-
tional File 3), since prescription rates may vary between
countries.
The following sensitivity analyses were performed. To
test the effect of a higher rate of drug-related hospitali-
sations, the complete model was calculated based on the
rate reported by Dormann [7]. Other one-way sensitivity
analyses examined upper and lower rates of specific
resource use (physician visits, emergency department
visits and hospitalisations) for ADEs, as reported in the
studies found (Table 2). In these sensitivity analyses, the
absolute numbers determined for base case healthcare
utilisation (Schneeweiss study) were applied and only
t h en u m b e r sf o rt h es p e c i f i cr e s o u r c ee x a m i n e d( e . g .
physician visits) were changed. The rates of healthcare
resource used from the literature review, adjusted
according to the population treated with medications in
the study (see Table 2) are multiplied with the popula-
tion treated with medications in Germany. The estimate
of the German population taking medications is based
on the percent of health insurance company members,
according to age, who had a medication prescribed in
2007 [26]. Percentages were adjusted for differences in
age and sex-distribution between the health insurance
population and the general population [27]. Overall,
about 75% of the German population over 20 years of
age (53.6 million of 66.2 million persons) take at least
one prescribed medication over the year. All calculations
were performed using Microsoft Excel.
Results
Base Case
The base case calculations using German data are
shown in Table 1. The base case estimates that 2.14 mil-
lion adults would develop ADEs during the course of
ambulatory medical treatment in 2007. Only 12% of
these patients require no extra healthcare services and
70% require only outpatient services such as a physician
Table 1 Annual resource use of the base case, resource unit costs and total costs of drug-related problems associated
with the outcomes of drug therapy according to probabilities of the model and population numbers
U.S. Data from Ernst et al.
2001 model [16]
German Data (Base Case)
Outcomes Overall probability
of therapeutic
outcome*
Factor in
relation to
hospitalisation
Expected population developing an ADE and classification
of resource utilization** (as % of population ingesting
medications)
Unit cost
(in 2007 €)
Total
costs
(million €)
No
treatment
0.0207 1.912 260,873 (0.5)
Physician
visit
0.0436 4.021 548,620 (1.1) 23
1 12.4
Additional
treatment
0.0753 6.944 947,451 (1.9) 42
2+23
1
(65
3)
61.8
Emergency
department
0.0166 1.531 208,887 (0.4) 437
4 91.3
Hospital
admissions
0.0108 1.000 136,447 (0.3) 3452
5 471.0
Long-term
care
0.0028 0.254 34,615 (0.07) 4890
6 169.3
Death 0.0002 0.022 2,958 (0.006) 3452
7 10.2
Total costs 816.0
*sum of probabilities associated with therapeutic outcomes in Figure 1 **calculated using the factor in relation to hospitalisation and the number of hospitalised
persons;
1average cost of published physician visits [20] inflated to year 2007;
2average cost of a prescribed medication in 2007 [19]
3Total cost of additional
treatment comprises physician visit and prescription of a new medication
4average cost per hospital day [18];
5average cost per hospital admission for an ADE
in 2007 (calculated by authors);
6average cost of 6 months of long-term facility care in 2007 (total service expenditures [23] divided by total beneficiaries [24];
7costs of death assume hospitalisation prior to death.
Table 2 Range of healthcare utilisation according to outpatient literature
Healthcare facilities used for
ADE/ADR
Healthcare utilisation per ADE/
ADR in %
Healthcare utilisation according to the population ingesting
medications in %
Physician visit 48.2 [36] - 88.7 [37] 3.5 [28] - 22.2 [29]
Emergency care 8.6 [29] - 15.7 [28] 0.9 [28] - 3.0 [29]
Hospitalisation 4.0 [38] - 12.4 [37] 0.50 [28] - 4.19 [29]
ADE: adverse drug event; ADR: adverse drug reaction; Study references are in square brackets
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the total German population taking medications, about
4.4% of the population ingesting medications in 2007
w o u l db ee x p e c t e dt oh a v ea nA D Ea n da b o u t3 . 8 %
would be expected to require health services. 3.0%
would require ambulatory medical care (physician visit
and additional treatment), 0.3% hospitalisation and
0.006% would die.
Expected resource use and cost estimates associated
with ADEs are also reported in Table 1 (costs of
resource utilisation and sources of costs are also shown
in the table). According to the model, ADEs may have
accounted for 816 million Euros of health care expendi-
tures in Germany over 1 year, with 80% of expenditures
for hospitalisation (also preceding death) and long-term
care being generated by 8% of the predicted patients
with ADEs. Ambulatory care, without the emergency
department, accounts for 9% of all costs but is required
by 70% of patients. Since 12% of patients with ADEs
generate no costs, the average cost of an ADE requiring
health services is 381 Euro if all persons with an ADE
are considered and 434 Euro if only those seeking
healthcare are considered.
Sensitivity Analysis
The sensitivity analyses in which the German hospitali-
sation rate [7] or only the rates of physician visits,
emergency department visits or hospitalisation individu-
ally are varied, are shown in Table 3. All rates are based
on the rates reported in the literature (Table 2) adjusted
according to the study population taking medications.
The sensitivity analysis (Table 3) shows that the esti-
mates based on the German hospitalisation rate
reported by Schneeweiss [8] are much lower than the
other estimates of the frequency and costs of ADEs.
The calculation using Dormann’s hospitalisation rate
has a strong effect on both the number of ADEs and
the costs postulated since the complete model is recal-
culated. Since the base case probabilities and resource
costs are used, the cost per case is equal to that of
Schneeweiss (381€). Dormann’s percentage of hospitali-
sations due to ADRs is still lower than other values
found in the literature. Variation of the number of phy-
sician visits has a large effect on the number of ADEs
but a small effect on the total costs and leads to lower
costs per case (upper limit: 117€ per case; lower limit:
358€ per case) than estimated by Schneeweiss. Variation
of the number of hospitalisations has the greatest effect
on the overall costs of ADEs. The upper limit of the
number of hospitalisations estimates total costs which
are 9 times higher than in the base case and costs per
case which are almost 5 times higher than costs per
case of the base case.
Discussion
This study uses a probability pathway model to estimate
the frequency and costs of ADEs occurring in ambula-
tory medical practice in Germany over 1 year (2007).
The model includes drug-related morbidity and mortal-
ity. It calculates ADEs and bases all resource utilisation
on the number of hospital admissions attributed to
ADEs reported by the German Schneeweiss study [8].
Results indicate that about 2 million ADEs have
occurred in persons in the population over 20 years of
age taking medications, and that subsequent health care
for 816 million Euros has been utilized.
The predicted probabilities of ADEs and resource uti-
lisation due to ADEs in the population treated with
medications were lower for the German base case than
in the original model, but close to the lower end of
rates reported in the literature, indicating a limited use-
fulness of the model in this respect. The calculation of
total costs of resource utilisation attributes the highest
proportion of costs to hospitalisation, the factor in the
model for which there are the most data for Germany.
Thus, in this respect, the model is useful in estimating
the lower limits of resource utilisation costs which can
be expected to be due to ADEs. According to the base
case, hospital admission due to an ADE is required by
0.3% of the population taking medications (see Table 1).
In comparison, the other German study predicts 0.4%
and the original NMP and TF/NMP arms of the model
together predict 1.1%. The studies of ADEs in ambula-
tory medical practice observed that between 0.5% [28]
and 4.2% [29] of the population taking medications
required hospitalisation due to an ADE (see Table 2).
These studies indicate that the base case likely underes-
timates the total number of ADEs, whereas the model
rates are likely too high for Germany. The original
model rates regarding mortality due to ADEs, 2.1% of
patients hospitalised for AD E s ,a r ea l s op r o b a b l yt o o
high for Germany, since Schneeweiss reported a rate of
1.7% and Dormann a rate of about 1%.
There are no German studies regarding other types of
resource utilisation for ADEs, such as physician or
emergency visits. However, the base case predicts rates
in the treated population of both physician visits (3%)
and emergency visits (0.4%) which are lower than those
predicted using Dormann’s study (5% and 0.7% respec-
tively), the original model (12% and 2% respectively) and
close to the lower end of rates reported in the literature
(3.5% and 0.9% respectively: see Table 2). Basing the
model on German hospitalisation rates to predict the
rates of ADEs in the outpatient population leads to esti-
mates of ADEs lower than reported in the literature.
According to the base case, 4.3% of the treated popula-
tion will have an ADE, whereas if Dormann’sv a l u e sa r e
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In the literature, probabilities for ADEs range between
5.5% [28] and 34.7% [29] of the treated population (see
Additional File 3).
As already implied above, this study has numerous
limitations. First, both studies used for the German data
are limited. The Schneeweiss study [8] reports admis-
sion rates due to ADRs which are considerably lower
than other studies but only non-elective admissions
were evaluated and patients with skin reactions were
not included. Also, the 3 hospitals in the study may not
have been representative for usual medical practice in
Germany. A follow-up study with intensified ADR sur-
veillance in these hospitals, reported a higher ADR inci-
d e n c er a t eo f3 . 2 5 %[ 3 0 ]w h i l eu s i n gt h eo r i g i n a l
exclusion criteria. The second German study was based
on admissions to a university hospital, which may have
a higher probability of ADE admissions. This study is
also limited by a smaller number of cases, a shorter
observation period, a baseline population which
included readmissions and transfers from other wards
and hospitals and the inclusion of ADRs due to che-
motherapeutic agents. Of further concern is that the ori-
gin of patients in both German studies is not described,
thus whether they were living independently or in a
nursing home is unknown. Also, both German studies
only report ADRs, a subgroup of ADEs. The gap
between the estimates for the base case and sensitivity
analyses (Table 3) also point out the gap in the available
information for Germany and the possible number of
unrecognised ADEs. The sensitivity analyses are also
limited, since all studies of ADEs in the ambulatory
population were performed in the USA and thus may
not reflect the incidence or resource use in Germany.
Due to its simple structure, the model does not reflect
all costs possibly incurred by ADEs, such as multiple
physician visits, multiple hospitalisations, increased costs
of health services around the time of death [31-34], or
other costly resources such as long-term dialysis for spe-
cific ADEs [35]. However, the use of a Markov model
would seem inappropriate at the present, since the lit-
erature provided neither exact treatment sequences for
ADEs, nor rates of recovery from ADEs.
Our estimations for the ambulatory sector show the
importance of hospital and long-term care costs, which
account for 80% of ADE costs but are generated by only
8% of patients predicted to have an ADE. In contrast,
costs of physician visits and additional treatment explain
9% of total ADE costs but are generated by 70% of
patients predicted to have an ADE. The overall costs
Table 3 Sensitivity analysis of variables contributing to the costs of drug-related morbidity and mortality model
Sensitivity analyses Limit Description of rate
used*
Resulting
Parameter Size
Resulting ADEs
(thousands)
Resulting costs of
ADEs (million €)
1. Comparison of effect of German
hospitalisation rates on model
Lower
(base
case)
Schneeweiss [8]: 2.4% of
medical admissions
Hospitalisations**:
139,405
2,140 816
Upper Dormann [7] : 3.8% of
medical admissions
Hospitalisations: 3,388 1,292
Total: 220,724
(Death: 4,684)
2. Variation in rate of physician visits
according to literature***
Lower 3.5% [28]
(total = 1,731,649)
Physician visits:
635,008
2,375 828
Additional
treatment:
1,096,640
Upper 22% [29]
(total = 11,075,753)
Physician visits:
4,061,560
11,719 1,291
Additional
treatment:
7,014,193
3. Variation in emergency department
visits according to literature
Lower 0.9% [28] 432,912 2,364 914
Upper 3.0% [29] 1,499,696 3,431 1,380
4. Change in only hospital admissions
according to literature
Lower 0.5% [28] Hospitalisations:
246,603
2,252 1,205
Deaths: 5346
Upper 4.2% [29] Hospitalisations:
2,051,109
4,096 7,569
Deaths: 44,466
*Rates refer to percentage of patients taking medications unless stated otherwise; **Equal to base case calculations; ***1/3 calculated as only physician visit and
2/3 rds with additional treatment).
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our estimates, but their calculations also include costs
for treatment failure, the most frequent drug-related
problem in their model. Generally, their cost structure
is similar, with hospitalisations and long-term care
accounting for 87% of all costs, while physician visits
and additional prescriptions account for 9.8% of costs.
Overall, the costs predicted by the sensitivity analyses
were much higher than the base case, indicating an
underestimation of true costs. However, all studies used
for the sensitivity analyses originated in the USA and
reflect the US population and health care system. This
attempt at transferring probabilities from a model devel-
oped for the USA to Germany, illustrates the extent of
required information which is still missing such as pre-
scribing practices, the rate of medication changes per
patient, estimates of compliance and the classes of med-
ications prescribed. The absence of universal healthcare
coverage in the US may have numerous consequences
on health care utilisation, such as rate of purchase of
prescribed medications, how closely patients are moni-
tored regarding medications and whether patients seek
medical advice if symptoms occur. The corresponding
behaviour and habits of patients and physicians in Ger-
many must be considered to decide how well these stu-
dies and rates apply in Germany.
Considering the limitations of the model and the para-
meters used, the postulated costs of 816 million Euros
(0.32% of German healthcare expenditures in 2007 (253
billion Euros) [17]), due to ADEs must be viewed with
caution. They represent first attempts for Germany to
postulate costs associated with ADEs emerging from
outpatient treatment and vividly illustrate the lack of
available data and difficulties in assessing any results.
Although outpatient research of ADEs may be difficult
in Germany, due to data confidentiality and the separa-
tion of in- and outpatient care, estimates based on the
model show that adverse drug events may be placing a
significant economic burden on the healthcare system in
Germany, especially in terms of hospital and long-term
care costs. As the population ages, the disease burden
will increase, more medications will be consumed and
the risk of severe adverse events and hospitalisation will
increase [3]. Investigations of outpatient ADEs in Ger-
many could determine the types of ADEs occurring and
useful prevention processes. At present, any calculations
assessing the benefits or costs related to processes aim-
ing at reducing adverse drug events, such as an electro-
n i ch e a l t hc a r d ,w o u l dr e q u i r em u c hm o r ed a t at h a n
available in the published literature in this area.
Conclusions
ADEs pose a significant problem in outpatient treatment
which may be preventable by improving communication
between pharmacists, physicians and patients. Studies
assessing the frequency of ADEs in the ambulatory set-
ting exist for the USA but were not found for Germany.
Costs related to ADEs in the ambulatory setting were
postulated using a cost-of-illness model. A major pro-
portion of these costs were attributed to hospitalisation
and to long-term care. Due to the paucity of informa-
tion regarding the ambulatory setting, it was difficult to
assess whether cases, resource use and costs were valid
for Germany. As all estimates in the sensitivity analysis
were higher, base case results can be considered a very
conservative estimate. To more precisely estimate the
population-related costs in Germany, reliable data would
be required on the prevalence of ADEs in general as
well as for specific medications and the share of ADEs
which are preventable.
Additional material
Additional file 1: Mean hospital costs calculated for each adverse
drug reaction described by Schneeweiss. All possible ICD codes which
are associated with an adverse drug reaction as described in the
Schneeweiss paper were determined using the German DRG grouper.
Using data from the Federal Office of Statistics for patients over 20 years
of age, the sum of hospital days reported for the possible ICD codes for
each described adverse drug reaction was divided by the total number
of patients with the ICD code to calculate an average length of stay. The
calculated average length of stay was multiplied with the average cost
per hospital day for general hospitals, 437€ [18].
Additional file 2: Mean overall hospital costs calculated using mean
costs of adverse drug reactions and weighting these according to
their frequency of occurrence in each drug class as described in the
paper by Schneeweiss. Mean overall weighted hospital costs were
calculated using the average hospital cost per adverse drug reaction
(ADR), shown in additional file 1 and weighting these costs according to
the frequency of these adverse drug reactions in the drug classes listed
in the Schneeweiss paper and then according to the proportion of the
drug classes as a total of all ADRs (also in the Schneeweiss paper).
Additional file 3: Literature review of studies examining the
frequency of adverse drug events in ambulatory patients. MEDLINE
was searched for studies reporting the frequency of adverse drug events
(ADEs) in adults in the ambulatory setting published after 1990. Studies
including chemotherapeutic agents or only certain diseases or specific
ADEs were excluded. The studies found in this search are listed and
summarized regarding their methodology and results.
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